EUVIMEDEUVIMED entdecken
Crossref

Exploring the link between carbamazepine- and lamotrigine-induced skin reactions and the HLA-A31:01 and HLA-B*1502 genetic markers

Saeid Charsouei, Sima Shahmohammadi Farid, Tayyar Nourollahi, Aynaz Asgharvand, Kia Tutunchi, Elyar Sadeghi Hokmabadi, Sona Abolhasani, Hamed Azar, Sina Hamzehzadeh, Behnaz Ahmadi, Seyyed Iman Jabraeili

Biomedicine Advances · 2025

DOI: 10.34172/bma.16 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedicine Advances, 2025. Verfasst von Saeid Charsouei und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Anticonvulsant drugs are valuable treatments for seizures and epilepsy. Carbamazepine (CBZ) and lamotrigine (LTG) are antiepileptic and mood-stabilizing drugs used to treat these diseases. The study aimed to investigate the relationship between the side effects of CBZ and LTG and the HLA-B*1502 and HLA-A31:01 alleles in Iranian patients with a seizure disorder.

Methods

This cross-sectional study was conducted on patients diagnosed with convulsions who visited Imam Reza and Razi Educational-Therapeutic Center, affiliated with Tabriz University of Medical Sciences, between March 2018 and March 2022. The blood samples of patients were analyzed by polymerase chain reaction for the presence or absence of HLA-B*1502 and HLA-A31:01 alleles.

Findings

In the HLA genetic analysis, the frequency of HLA-A31:01 was found to be 3.1%, and all three carriers of the HLA-A31:01 allele were in the first group; however, the difference between the studied groups was not statistically significant (P=0.07). The prevalence of the HLA-B 1502 gene in low resolution was 5.2%, which included 2 (4.2%) patients in the first group and 3 (6.1%) patients in the second group (P=0.66). None of these patients carried the HLA-B 1502 genotype in the high-resolution analysis. In the subgroup analysis of CBZ recipients, the prevalence of HLA-A31:01 was found to be 4.5%, and all three HLA-A31:01 patients were in the first group; however, the difference between the examined groups was not statistically significant (P>0.05). In the LTG subgroup analysis, HLA-B15:02 did not indicate a significant difference between the two groups (P>0.05).

Conclusion

In the present study, which involved 97 patients, no correlation was found between the genetic markers HLA-B*1502 and HLA-A31:01 and skin reactions triggered by antiepileptic drugs.

Zitieren

APA

Charsouei, S., Farid, S. S., Nourollahi, T., Asgharvand, A., Tutunchi, K., Hokmabadi, E. S., Abolhasani, S., Azar, H., Hamzehzadeh, S., Ahmadi, B., & Jabraeili, S. I. (2025). Exploring the link between carbamazepine- and lamotrigine-induced skin reactions and the HLA-A31:01 and HLA-B*1502 genetic markers. Biomedicine Advances. https://doi.org/10.34172/bma.16

Vancouver

Charsouei S, Farid SS, Nourollahi T, Asgharvand A, Tutunchi K, Hokmabadi ES, et al. Exploring the link between carbamazepine- and lamotrigine-induced skin reactions and the HLA-A31:01 and HLA-B*1502 genetic markers. Biomedicine Advances. 2025. doi:10.34172/bma.16

BibTeX
@article{Charsouei2025,
  author = {Charsouei, Saeid and Farid, Sima Shahmohammadi and Nourollahi, Tayyar and Asgharvand, Aynaz and Tutunchi, Kia and Hokmabadi, Elyar Sadeghi and Abolhasani, Sona and Azar, Hamed and Hamzehzadeh, Sina and Ahmadi, Behnaz and Jabraeili, Seyyed Iman},
  title = {Exploring the link between carbamazepine- and lamotrigine-induced skin reactions and the HLA-A31:01 and HLA-B*1502 genetic markers},
  journal = {Biomedicine Advances},
  year = {2025},
  doi = {10.34172/bma.16}
}
Kostenlos starten →